Roche scores double cancer approval for new Bayer rival Rozlytrek
admin 15th August 2019 Uncategorised 0Roche’s targeted cancer drug Rozlytrek officially has its U.S. green light—and in not just one, but two cancer types. Thursday, the FDA cleared the med to treat ROS1-positive non-small cell lung cancer and tough-to-treat NTRK fusion-positive tumors.
More: Roche scores double cancer approval for new Bayer rival Rozlytrek
Source: fierce